Development of new chitosan/carrageenan nanoparticles for drug delivery applications by Grenha, Ana et al.
Development of new chitosan/carrageenan nanoparticles
for drug delivery applications
Ana Grenha, Manuela E. Gomes, Ma´rcia Rodrigues, Vı´tor E. Santo, Joa˜o F. Mano,
Nuno M. Neves, Rui L. Reis
Department of Polymer Engineering, University of Minho, 3Bs Research Group, Biomaterials, Biodegradables and
Biomimetics, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine,
IBB Institute for Biotechnology and Bioengineering, PT Government Associated Laboratory, Portugal
Received 6 September 2008; revised 17 December 2008; accepted 29 January 2009
Published online 25 March 2009 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/jbm.a.32466
Abstract: The use of polymeric nanoparticles, especially
those composed of natural polymers, has become a very
interesting approach in drug delivery, mainly because of
the advantages offered by their small dimensions. The aim
of this work was to develop a novel formulation of nano-
particles comprised of two natural marine-derived poly-
mers, namely chitosan and carrageenan, and to evaluate
their potential for the association and controlled release of
macromolecules. Nanoparticles were obtained in a hydro-
philic environment, under very mild conditions, avoiding
the use of organic solvents or other aggressive technologies
for their preparation. The developed nanocarriers pre-
sented sizes within 350–650 nm and positive zeta poten-
tials of 50–60 mV. Polymeric interactions between nanopar-
ticles’ components were evaluated by Fourier transform
infrared spectroscopy. Using ovalbumin as model protein,
nanoparticles evidenced loading capacity varying from 4%
to 17% and demonstrated excellent capacity to provide a
controlled release for up to 3 weeks. Furthermore, nano-
particles have demonstrated to exhibit a noncytotoxic
behavior in biological in vitro tests performed using L929
ﬁbroblasts, which is critical regarding the biocompatibility
of those carriers. In summary, the developed chitosan-car-
rageenan nanoparticles have shown promising properties
to be used as carriers of therapeutic macromolecules, with
potential application not only strictly in drug delivery, but
also in broader areas, such as tissue engineering and
regenerative medicine.  2009 Wiley Periodicals, Inc.
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INTRODUCTION
Natural polymers have been gaining increasing in-
terest in the biomedical ﬁeld and particularly in the
area of drug delivery, either intrinsically or in the con-
text of broader ﬁelds, such as tissue engineering.
Amongst these polymers, polysaccharides found a
wide variety of applications, given their participation
in important functions of the organism, like membrane
structure and intracellular communication, and also
because of their ﬂexibility, which allows polysaccha-
rides to form both linear and branched polymers.1
Chitosan is a polymer of natural origin, which is
composed of repeating units of N-acetylglucosamine
and D-glucosamine, being obtained from the deacety-
lation of chitin, the main component of the exoskele-
ton of crustaceans.2–4 This polysaccharide possesses
structural characteristics similar to those displayed
by glycosaminoglycans (GAGs), which are an impor-
tant component of connective tissues and, owing to
that feature, chitosan has been investigated for a
range of biomedical applications, such as wound
healing, tissue engineering, dentistry, and orthope-
dics.4 This polymer presents well-documented favor-
able biological properties such as biocompatibility,
biodegradability, and low toxicity,5,6 and it also dis-
plays mucoadhesive properties,7 rendering this mol-
ecule very attractive for drug delivery applications.
Carrageenan is also a polysaccharide, extracted
from red seaweed, which is composed of galactose
and anhydrogalactose units, linked by glycosidic
unions. Depending on the method and the algae
from which carrageenan is extracted, three main
types of carrageenans can be obtained, kappa (j),
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iota (i), and lambda (k), which mainly differ struc-
turally in the degree of substitution of the sulfate
group.8 Given the ionic nature of the polymer, its ge-
lation is strongly inﬂuenced by the presence of
electrolytes and, from these three types, only k- and
i-carrageenans evidence gel-forming ability, the k-car-
rageenan gels being more ﬁrm than those obtained
with i-carrageenan, which are more elastic and soft.9
When two polyelectrolytes of opposite charge are
combined, the formation of a physical hydrogel
might take place, which is called ionotropic hydro-
gel. This hydrogel is held together by molecular
entanglements, ionic forces, H-bonding, or hydro-
phobic forces.10 All these interactions are reversible
and can be disrupted by changes in physical condi-
tions such as ionic strength, pH, and temperature.8
Depending on the concentrations of the polyelectro-
lytes, different gel-structures can be produced, such
as beads, microparticles, or nanoparticles. Polyelec-
trolyte complexes of chitosan and carrageenan in the
form of beads and tablets were previously reported
to efﬁciently deliver sodium diclofenac and diltia-
zem hydrochloride, respectively.11,12 The formulation
of nanoparticles as drug delivery systems would be
very advantageous. In fact, because of their small
dimensions, surface-to-volume ratio and surface func-
tionality are enormously increased, rendering nanopar-
ticles very promising vehicles for drug delivery.13,14
In this work, we report the preparation and charac-
terization of protein-loaded nanoparticles obtained by
ionic complexation of chitosan and carrageenan, as a
valuable drug delivery system. For this purpose, we
chose ovalbumin as model protein to be associated to
the nanoparticles. Chitosan and carrageenan are natu-
rally occurring polymers and are approved for appli-
cations in the food industry. Protein-loaded chitosan/
carrageenan nanoparticles were obtained by means of
ionic complexation between the polyelectrolytes; their
physicochemical and morphological properties were
characterized and their ability to deliver the encapsu-
lated macromolecule was evaluated in vitro. More-
over, the biocompatibility of the nanoparticles was
assessed using a rat ﬁbroblasts cell line.
MATERIALS AND METHODS
Materials
Chitosan (CS) (low molecular weigh, deacetylation
degree 5 75–85%), albumin from chicken egg white (oval-
bumin) grade V, tungstophosphoric acid, phosphate buf-
fered saline tablets (PBS) pH 7.4, Dulbecco’s modiﬁed
Eagle’s medium low glucose, Dulbecco’s modiﬁed Eagle’s
medium without phenol red and sodium bicarbonate were
purchased from Sigma Chemicals (Germany). K-carra-
geenan (CRG) was obtained from Fluka Biochemica (Ger-
many) and gycerol from Riedel-del-Hae¨n (Germany). Fetal
bovine serum (FBS) was from Biochrom AG, (Germany)
and antibiotic-antimycotic (A/B) solution from Gibco
(Spain). MTS was purchased from Promega (UK). Ultra-
pure water (TKA, Germany) was used throughout. All
other chemicals were reagent grade.
Determination of chitosan average
viscosity molecular weight
Prior to the determination of chitosan average viscosity
molecular weight, chitosan was puriﬁed by a recrystaliza-
tion procedure. Brieﬂy, chitosan was dissolved in 1% (v/v)
acetic acid in order to achieve a concentration of 1 mg/
mL. On complete dissolution, chitosan was ﬁltered and
neutralized with NaOH until pH 8. The obtained precipi-
tate was afterwards washed with water and freeze-dried
for 4 days (Telstar Cryodos E79LH, IMA-Telstar, Spain).
To determine chitosan molecular weight, the puriﬁed
chitosan was dissolved in 1% (v/v) acetic acid to obtain
different solutions in a range of concentrations, which
were assayed for their ﬂow time in a viscosimeter (MGW
Werk Lauda, model D6970, Germany). Afterwards, the
Mark-Houwink Eq. (1) was applied to determine the mo-
lecular weight (MW):
½h ¼ kðMWÞa ð1Þ
where [h] is the intrinsic viscosity, determined by the vis-
cosimeter, k 5 3.5 3 1024 and a 5 0.76.15
Preparation of chitosan/carrageenan nanoparticles
Chitosan/carrageenan (CS/CRG) nanoparticles were
prepared by ionic complexation,16 by means of an electro-
static interaction of CS with CRG anions, in which the pos-
itively charged amino groups of CS interact with the nega-
tively charged sulfate groups of CRG. Brieﬂy, CS was dis-
solved in 1% (v/v) acetic acid and CRG was dissolved in
puriﬁed water at 608C, to obtain solutions of 1 mg/mL
(w/v) and 0.42 to 0.71 mg/mL (w/v), respectively, to
reach ﬁnal theoretical CS/CRG ratios of 3.5/1, 4/1, 5/1,
and 6/1 (w/w). The nanoparticles were spontaneously
formed on incorporation of 1.2 mL of the different concen-
tration CRG solutions into 3 mL of the CS solution, under
magnetic stirring at room temperature. To prepare the pro-
tein-loaded CS/CRG nanoparticles, ovalbumin was dis-
solved in water (solution pH 5 6.2) and further incorpo-
rated in the CRG solution afterwards (pH 5 7.6). The con-
centration of ovalbumin in the CRG solution was such that
allowed preparing nanoparticles with 10, 20, and 30% (w/
w) of protein respective to the CS content. Nanoparticles
were concentrated by centrifugation at 11,500g on a 10-lL
glycerol layer, for 30 min (Biocen, Orto Alresa, Spain),
glycerol being used to aid the subsequent resuspension.
The supernatants were discarded and nanoparticles were
resuspended in 100 lL of puriﬁed water.
Determination of nanoparticles production yield
The nanoparticles production yield was determined by
gravimetry. For this purpose, ﬁxed volumes of nanoparticle
suspensions were centrifuged (11,500g, 30 min) and sedi-
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ments were freeze-dried over 24 h, using a Telstar Freeze
Dryer (Telstar Cryodos E79LH, IMA-Telstar, Spain) (n 5 4).
The process yield was calculated as follows:
Process yield ð%Þ ¼ Nanoparticles weight
Total solids weight
3 100 ð2Þ
where nanoparticles weight is the sediment weight after
freeze-drying and total solids weight is the total amount of
solids added for nanoparticles formation (chitosan and car-
rageenan for unloaded nanoparticles and chitosan, carra-
geenan, and ovalbumin for protein-loaded nanoparticles).
Characterization of nanoparticles
Morphology
The morphological analysis of the nanoparticles devel-
oped in this study was performed by transmission electron
microscopy (TEM) (CM 12 Philips, Eindhoven, Nether-
lands). Before TEM observation, samples were stained
with 2% (w/v) tungstophosphoric acid and placed on cop-
per grids with Formvar1 ﬁlms.
Physicochemical properties
The size and zeta potential of the nanoparticles were
measured by photon correlation spectroscopy and laser
Doppler anemometry, respectively, using a Malvern Zeta-
sizer1 3000 HS (Malvern Instruments, UK). For the parti-
cle size analysis, each sample was diluted to the appropri-
ate concentration with water. Each analysis lasted 120 s
and was performed at 258C with a detection angle of 908.
For the determination of the electrophoretic mobility, sam-
ples were diluted with KCl 0.1 mM. Each formulation was
analyzed in triplicate (n 5 3).
Fourier transform infrared
The interactions between the different components of the
nanoparticulate systems were analyzed by Fourier transform
infrared (FTIR). Infra-red spectra of the specimen powders,
namely chitosan, carrageenan, and chitosan/carrageenan
nanoparticles, were recorded using a FTIR spectrophotome-
ter (Shimadzu, IR Prestige-21, Japan). Prior to the assay, the
samples were gently triturated with KBr (Riedel-del-Hae¨n,
Germany) and compressed into discs by pressing the pow-
ders. For each spectrum a 32-scan interferogram was col-
lected in absorption with a 4 cm21 resolution from the 4000–
400 cm21 region at room temperature.
Determination of the in vitro cytotoxicity of the
chitosan/carrageenan nanoparticles
L929 ﬁbroblasts cell line
Mouse ﬁbroblastic-like cell line L929, obtained from
ECACC (UK), was grown in a humidiﬁed 5% CO2/95%
atmospheric air incubator, at 378C, using 75 cm2 ﬂasks.
The culture was maintained with Dulbecco’s Modiﬁed
Eagle’s Medium low glucose (DMEM), supplemented with
10% fetal bovine serum (FBS), 1% antibiotic-antimycotic
(A/B) solution, and sodium bicarbonate. Medium was
changed every 3 days.
MTS test
The in vitro cytotoxicity of chitosan/carrageenan nano-
particles in the L929 cells was determined by the MTS (3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2-tetrazolium) assay. Cells were seeded at a
density of 4 3 103 cells/well in 96-well Costar ﬂat bottom
plates (Corning, USA), cultured with 200 lL of the medium
used to expand L929 cells, and allowed to grow at 378C in a
5% CO2 atmosphere for 24 h, before cell viability assays.
Before incubation with the test formulations, the culture me-
dium was aspirated and the cells washed with PBS pH 7.4.
The chitosan/carrageenan nanoparticles (CS/CRG 5 3.5/
1) were assayed for cytotoxicity at different concentrations
(0.1, 1, and 3 mg nanoparticles/mL) for 1, 3, and 7 days in
direct contact with L929 cells. Six replicates were considered
per sample. All formulations were prepared as suspensions
in prewarmed DMEM without phenol red containing 10%
FBS and 1% A/B, immediately before their application to
the cells. L929 cells relative viability (%) was determined for
each concentration of nanoparticles and compared with that
of cells incubated only with cell culture medium without
phenol red. Latex discs were used as a positive control of
cell death. All tests were performed in triplicate.
Determination of protein loading capacity
of nanoparticles
The nanoparticles association efﬁciency was determined
upon their separation from the preparation medium con-
taining the nonassociated protein by centrifugation
(11,500g, 30 min). The amount of free ovalbumin was
determined in the supernatant by the MicroBCA protein
assay (Pierce, USA), measuring the absorbances by spec-
trophotometry (Shimadzu UV-Visible Spectrophotometer
UV-1603, Japan) at 562 nm. A calibration curve was made
using the supernatant of blank nanoparticles. Each sample
was assayed in triplicate (n 5 3). The nanoparticles’ pro-
tein association efﬁciency and loading capacity were calcu-
lated from Eqs. (3) and (4) indicated below:
Association efficiency ð%Þ
¼ Total amount of protein Free amount of protein
Total amount of protein
3 100
ð3Þ
Loading capacity ð%Þ
¼ Total protein amount Free protein amount
Nanoparticles weight
3 100
ð4Þ
In vitro release studies of ovalbumin
from CS/CRG nanoparticles
The release of ovalbumin was determined by incubating
the nanoparticles (CS/CRG 5 3.5:1 containing 30% w/w
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ovalbumin based on chitosan) in 12 mL of pH 7.4 phos-
phate buffer (0.076 mg nanoparticles/mL), with horizontal
shaking, at 378C. Ovalbumin was in sink conditions (oval-
bumin solubility at pH 7 is 40 mg/mL).
At appropriate time intervals (up to 3 weeks) individual
samples were ﬁltered (0.22-lm ﬁlters Millex1-GV, low
protein binding, Millipore, Portugal) and the amount of
protein released evaluated in the supernatants by the
MicroBCA protein assay (Pierce, USA) measuring the ab-
sorbances by spectrophotometry (Shimadzu UV-Visible
Spectrophotometer UV-1603, Japan) at 562 nm (n 5 3).
Statistical analysis
The t-test and the one-way analysis of variance
(ANOVA) with the pairwise multiple comparison proce-
dures (Student-Newman-Kleus Method) were performed
to compare two or multiple groups, respectively. All anal-
yses were run using the SigmaStat statistical program
(Version 3, SyStat, USA) and differences were considered
to be signiﬁcant at a level of p < 0.05.
RESULTS AND DISCUSSION
Preparation and characterization of chitosan/
carrageenan nanoparticles
The average viscosity molecular weight of chitosan
was determined to be 116 KDa, as obtained by the
Mark-Houwink equation (data not shown).
Although the technique of ionic complexation was
applied in other occasions to obtain chitosan nano-
particles by interaction with counter-anions, such as
tripolyphosphate or dextran sulfate,16,17 the present
work reports for the ﬁrst time the production of chi-
tosan nanoparticles by complexation with carra-
geenan, a natural polymer obtained from seaweed.
Chitosan/carrageenan (CS/CRG) nanoparticles
were successfully obtained using a 1 mg/mL CS so-
lution and CS/CRG mass ratios of 3.5/1, 4/1, 5/1,
and 6/1, by means of an electrostatic interaction
between the positively charged chitosan amino
groups and the oppositely charged sulfate groups of
carrageenan. Ratios above 3.5/1 led to thorough pre-
cipitation, whilst mass ratios under 6/1 did not lead
to the formation of nanoparticles. This is attributed
to the fact that when high CS/CRG mass ratios are
employed (for instance, 2/1 or 3/1) the amount of
carrageenan is too high compared with the chitosan
amino groups available for neutralization, thus lead-
ing to precipitation. On the contrary, when the
amount of carrageenan is too low (for example in a
mass ratio of 7/1), the amount of counter-anion is
not sufﬁcient to lead to the formation of nanopar-
ticles. Figure 1 displays the TEM microphotograph
of representative CS/CRG nanoparticles, which evi-
dence a solid and compact structure, showing a
tendency to exhibit a spherical-like shape.
As shown in Table I, the nanoparticles production
yield was inﬂuenced by the CS/CRG ratio. More
speciﬁcally, the incorporation of increasing amounts
of CRG with respect to CS, led to a slight increase in
the process yield, which is actually signiﬁcantly
higher for the formulation with CS/CRG mass ratio
of 3.5/1 (p < 0.05), which achieved the maximum
yield (27%). This effect can be easily explained by
the nanoparticles formation mechanism: as men-
tioned above, nanoparticles are formed as result of
the interaction of the positively charged CS mole-
cules with the counter-anion CRG and, therefore, the
incorporation of higher amounts of CRG (lower CS/
CRG theoretical ratios) leads to the formation of a
greater number of particles.18
As revealed by the photon correlation spectros-
copy and laser Doppler anemometry analyses,
unloaded CS/CRG nanoparticles displayed a particle
size in the nanometric range, between 430 nm and
640 nm, and a positive zeta potential within þ55 mV
and þ60 mV. The nanoparticles size increased
progressively and signiﬁcantly (p < 0.05) with the
Figure 1. TEM microphotograph of chitosan/carrageenan
(3.5/1) nanoparticles.
TABLE I
Production Yields and Physicochemical Characteristics
of Unloaded Chitosan/Carrageenan (CS/CRG)
Nanoparticles (Mean 6 S.D.)
CS/CRG
Production
Yield (%)
Size
(nm)
Zeta
Potential (mV)
3.5/1 27 6 1 634 6 54 þ55.9 6 1.0
4/1 21 6 4 577 6 13 þ55.3 6 0.9
5/1 20 6 2 500 6 11 þ60.2 6 0.3
6/1 18 6 4 430 6 22 þ59.2 6 2.2
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incorporation of increasing amounts of carrageenan
(CS/CRG 5 6/1 to 3.5/1). This is quite logical, since
carrageenan is a large polymer and, thus, higher
amounts (CS/CRG 5 3.5/1) led to the formation of
larger particles. Higher amounts of CRG resulted in
lower zeta potential values, the formulations 3.5/1
and 4/1 presenting a lower surface charge (p < 0.05)
as compared with formulations 5/1 and 6/1. This
effect can be attributed to the higher neutralization
of the CS positive amino groups by the negatively
charged sulfate groups of CRG.19
The association of ovalbumin as model protein
was investigated for nanoparticles with CS/TPP
ratios of 3.5/1 and 4/1, because those were the con-
ditions showing higher production yields. The com-
parison of results presented in Tables I and II, corre-
sponding to the unloaded and the ovalbumin-loaded
nanoparticles, respectively, indicated that nanopar-
ticles’ size decreased signiﬁcantly (p < 0.05) with the
incorporation of ovalbumin in both formulations
with either 10, 20, or 30% initial amount of ovalbu-
min. This decrease was from 634 nm (unloaded
nanoparticles) to approximately 400–450 nm (ovalbu-
min-loaded) in the formulation CS/CRG 5 3.5/1
and from 577 nm (unloaded nanoparticles) to 350–
400 nm (ovalbumin-loaded) in formulation 4/1. This
reduction in size is possibly due to an effect of retic-
ulation of the particles induced by the presence of
the protein.
The incorporation of ovalbumin in the nanopar-
ticles led, in some cases, to a statistically signiﬁcant,
although minor in value, decrease of zeta potential
(p < 0.05), particularly for the formulation 3.5/1.
Taking into account that ovalbumin is dissolved in
water, the protein is above its isoelectric point (pI
4.6), resulting in a negative charge. As a conse-
quence, its association with the positively charged
CS/CRG nanoparticles is favored, causing a decrease
in the zeta potential value.
As it can be observed in Figure 2, protein entrap-
ment ranged between 12 and 18% [Fig. 2(a)] and the
loading of ovalbumin varied within 4 and 17% [Fig.
2(b)]. Incorporating different initial amounts of oval-
bumin (10, 20, and 30%) to the formulation of CS/
CRG nanoparticles 3.5/1 did not lead to signiﬁcant
differences in the association efﬁciency [Fig. 2(a)].
However, in the formulation 4/1, there was a sta-
tistical signiﬁcant difference (p < 0.05) between the
association efﬁciencies of 10, 20, and 30%; the maxi-
mum association observed for the 30% ovalbumin
(17% of association) (p < 0.05). This is probably the
result of adding a higher amount of protein, so that
more protein is available for interaction with the chi-
tosan molecules, although the maximum difference
is only of 5% (comparing the 17% association of the
formulation with 30% of initial amount, with the
12% association of the formulation with 10% initial
amount). The different behavior observed between
the formulations CS/CRG 3.5/1 and 4/1, one reveal-
ing concentration dependent association and the
other an absence of this effect, could be attributed to
the highest amount of carrageenan present in the
formulation 3.5/1, which could therefore compete
with ovalbumin for the chitosan amino groups.
Comparing the association obtained for the formu-
lation CS/CRG 5 3.5/1 with that of 4/1 for each of
the concentrations, a signiﬁcant difference (p < 0.05)
is found only in the case of 10% of initial amount of
ovalbumin, the formulation 3.5/1 associating 18% as
compared with the 12% of 4/1. The highest loading
TABLE II
Production Yields and Physicochemical Characteristics of
Ovalbumin-Loaded Chitosan/Carrageenan (CS/CRG)
Nanoparticles (mean 6 S.D.)
CS/CRG
Initial
Amount
of Protein
(%)a
Production
Yield
(%)
Size
(nm)
Zeta
Potential
(mV)
3.5/1 10 20 6 3 446 6 14 þ49.5 6 3.4
3.5/1 20 21 6 3 458 6 31 þ50.3 6 1.1
3.5/1 30 19 6 2 402 6 28 þ49.4 6 1.6
4/1 10 20 6 3 413 6 52 þ49.8 6 1.3
4/1 20 18 6 2 346 6 46 þ52.9 6 3.3
4/1 30 18 6 4 356 6 22 þ54.2 6 2.1
aRelative to chitosan (w/w).
Figure 2. (a) Encapsulation efﬁciency and (b) loading
capacity of ovalbumin in chitosan/carrageenan (CS/CRG)
nanoparticles (u CS/CRG 5 3.5/1; CS/CRG 5 4/1)
(n 5 3; mean 6 SD).
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efﬁciency (around 17%) was observed for the formu-
lations to which an initial amount of 30% ovalbumin
was added. This is closely related to the fact that
these formulations associated a higher amount of
protein, while maintaining a production yield similar
to the other formulations, so that they have more
protein in the same amount of total solids.
FTIR
Figure 3 displays the FTIR spectra obtained from
the analysis of chitosan, carrageenan, and the nano-
particles obtained by complexation of both polymers.
As expected, chitosan revealed the very typical peak
of amide I at 1654 cm21 11,20,21 and a peak at 1596
cm21, which has been attributed to amide II.20,21
Moreover, a peak corresponding to the glycosidic
bonds was identiﬁed at 1086 cm21.20
The FTIR analysis of k-carrageenan showed sev-
eral peaks, from which it is important to highlight a
peak at 1242 cm21 corresponding to the sulfate
groups, a peak at 1072 cm21 attributed to the glyco-
sidic linkage, a peak at 923 cm21 which corresponds
to the 3,6-anhydrogalactose and another at 848 cm21,
corresponding to galactose-4-sulfate.11,22,23 The FTIR
spectra of the nanoparticles obtained upon complex-
ation of chitosan and carrageenan showed a new
absorption band at 1530 cm21, assigned to NH3þ
groups, which is absent in both spectra of chitosan
and carrageenan. Both amide peaks of chitosan con-
verted into a singlet band at 1639 cm21, and NH2
groups are still identiﬁed because not all became
protonated and available for interaction with carra-
geenan. Typical bands of carrageenan were identi-
ﬁed in the nanoparticles spectrum, such as sulfate
groups at 1249 cm21, 3,6-anhydrogalactose at 927
cm21, and galactose-4-sulfate at 848 cm21. These
results evidence the formation of nanoparticles by
complexation between the oppositely charged poly-
saccharides chitosan and carrageenan.
In vitro release studies
Figure 4 depicts the release proﬁle of ovalbumin
from nanoparticles (CS/CRG ratio of 3.5:1) in PBS pH
7.4 at 378C. As can be observed, the developed chito-
san/carrageenan nanoparticles showed a sustained
release of ovalbumin for a period of 3 weeks. This
pattern of release is very promising because it is not
only very close to zero order release kinetics, but also
because it is sustained for an extended period.
This in vitro release behavior indicates that ovalbu-
min is in fact encapsulated in the solid matrix of the
nanoparticles, not just being distributed through the
particles’ surface, which usually leads to an initial
burst effect. Therefore, it is suggested that ovalbu-
min established a strong interaction with the nano-
particles. Given the negative charge of ovalbumin
(pH above its isoelectric point), the protein is able to
interact with the positively charged chitosan amino
groups. This controlled release proﬁle is extremely
important, since it allows incorporating a deter-
mined amount of molecule inside a carrier, which
will release for a prolonged period of time without
the need of repeated administrations. If we consider
the use of these nanocarriers, for instance, in the
ﬁeld of tissue engineering/regenerative medicine,
the particles could provide an adequate release pro-
ﬁle for a speciﬁc growth factor on implantation of
the device in the affected area.
In vitro cytotoxicity studies
Figure 5 displays the relative viability of L929 cells
upon exposure to different concentrations of CS/
Figure 3. FTIR spectra of chitosan (CS), k-carrageenan
(CRG), and CS/CRG nanoparticles.
Figure 4. Ovalbumin release proﬁle from chitosan-carra-
geenan (CS/CRG 5 3.5/1) nanoparticles in PBS pH 7.4 at
378C (ovalbumin 5 30% (w/w) based on chitosan; mean 6
SD; n  3).
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CRG nanoparticles (0.1, 1, and 3 mg nanoparticles/
mL) for 1, 3, and 7 days. As can be observed, the
lowest concentrations of nanoparticles, 0.1 and
1 mg/mL, generally did not evidence a signiﬁcant
effect on cells viability, when compared with cells
incubated with culture medium. The cells show a vi-
ability of over 80% during the experiments with
those concentrations of nanoparticles when com-
pared with the negative control.
The highest concentration of nanoparticles assayed
evidenced low levels of cellular viability (p < 0.05),
similar to the latex leachables used as positive con-
trol. However, it is important to highlight here that
the production of nanoparticles implies their resus-
pension in water on isolation by centrifugation. This
step cannot be avoided and the amount of water
was reduced to the minimum possible. Nevertheless,
given the high concentration of nanoparticles needed
for the assay (3 mg/mL), the amount of cell culture
medium was low and the nutrients provided for the
L929 cells are likely to be insufﬁcient to keep
the cells growing. Therefore, we believed that the
observed cytotoxicity is probably due to the lack of
sufﬁcient culture medium (and thus nutrients for the
cells) and not to the presence of the nanoparticles
itself. To demonstrate this hypothesis, an experimen-
tal control was tested by culturing L929 cells in a so-
lution with the same proportion of water/culture
medium as used for the 3 mg/mL nanoparticles con-
centration. As observed in Figure 5, the obtained rel-
ative viability of this control is generally similar to
that displayed for the nanoparticles at a concentra-
tion of 3 mg/mL. Therefore, in summary, the devel-
oped chitosan/carrageenan nanoparticles were dem-
onstrated to be noncytotoxic, under a range of con-
centrations between 0.1 and 3 mg/mL.
CONCLUSIONS
This work demonstrates that the newly developed
chitosan and carrageenan nanoparticles are suitable
to be used as controlled and sustained drug release
systems. These nanoparticles are produced in com-
plete hydrophilic conditions, by a very mild proce-
dure of ionic interaction between the positively
charged chitosan amino groups and the oppositely
charged sulfate groups of carrageenan. This proce-
dure avoids the use of organic solvents and other
aggressive conditions that might be detrimental for
the integrity of the drug to be released. The macro-
molecule ovalbumin, used in this study as model
protein, was efﬁciently associated to the developed
drug delivery systems, as demonstrated by the phys-
icochemical characterization of the system. The
in vitro release assay demonstrated that the chito-
san/carrageenan nanoparticles provided a sustained
and controlled release of the protein for an extended
period of three weeks. Moreover, the developed
nanocarriers exhibited low toxicity in contact with
ﬁbroblast-like cells, which is an encouraging indica-
tor of their biocompatibility and safety. The con-
trolled release proﬁle and the absence of overt toxic-
ity, make these nanoparticles strong candidates for
many biomedical applications, as drug delivery
carriers and in the context of tissue engineering
strategies.
References
1. Malafaya P, Silva G, Reis R. Natural-origin polymers as car-
riers and scaffolds for biomolecules and cell delivery in tissue
engineering applications. Adv Drug Deliv Rev 2007;59:207–
233.
2. Kurita K. Chitin and chitosan: Functional biopolymers from
marine crustaceans. Marine Biotechnol 2006;8:203–226.
3. Muzzarelli RAA. Chitin. In: Aspinall GO, editor. The Polysac-
charides. Orlando: Academic Press; 1985. p 417–450.
4. Singh DK, Ray AR. Biomedical applications of chitin, chito-
san and their derivatives. Rev Macromol Chem Phys C
2000;40:69–83.
5. Dornish M, Hagen A, Hansson E, Peucheur C, Vedier F,
Skaugrud O. Safety of ProtasanTM: Ultrapure chitosan salts
for biomedical and pharmaceutical use. In: Domard A, Rob-
erts GAF, Varum KM, editors. Advances in Chitin Science.
Lyon: Jacques Andre; 1997. p 664–670.
6. Hirano S, Seino H, Akiyama Y, Nonaka I. Biocompatibility of
chitosan by oral and intravenous administrations. Polym
Mater Sci Eng 1988;59:897–901.
7. Lehr CM, Bouwstra JA, Schacht EH, Junginger HE. In vitro
evaluation of mucoadhesive properties of chitosan and some
other natural polymers. Int J Pharm 1992;78:43–48.
8. Sankalia MG, Mashru RC, Sankalia JM, Sutariya VB. Stability
improvement of alpha-amylase entrapped in kappa-carra-
geenan beads: Physicochemical characterization and optimi-
zation using composite index. Int J Pharm 2006;312:1–14.
9. Bixler HJ. The carrageenan connection IV. British Food J
1994;96:12–17.
Figure 5. L929 relative cell viability measured by MTS
cytotoxicity assay after 1, 3, and 7 days exposure to
increasing concentrations of chitosan/carrageenan nano-
particles. Data represent mean 6 SEM (n 5 3 experiments,
six replicates per experiment at each test concentration).
NEW CHITOSAN/CARRAGEENAN NANOPARTICLES FOR DRUG DELIVERY APPLICATIONS 1271
Journal of Biomedical Materials Research Part A
10. Prestwich GD, Marecak DM, Marececk JF, Vercruysse KP,
Ziebell MR. Controlled chemical modiﬁcation of hyaluronic
acid: Synthesis, applications, and biodegradation of hydra-
zide derivatives. J Control Release 1998;53:93–103.
11. Tapia C, Escobar Z, Costa E, Sapag-Hagar J, Valenzuela F,
Basualto C, Gai MN, Yazdani-Pedram M. Comparative studies
on polyelectrolyte complexes and mixtures of chitosan-alginate
and chitosan carrageenan as prolonged diltiazem chorhydrate
release systems. Eur J Pharm Biopharm 2004;57:65–75.
12. Piyakulawat P, Praphairaksit N, Chantarasiri N, Muangsin N.
Preparation and evaluation of chitosan/carrageenan beads
for controlled release of sodium diclofenac. AAPS Pharmsci-
Tech 2007;8:E1–E11.
13. Kim K, Fisher JP. Nanoparticle technology in bone tissue en-
gineering. J Drug Target 2007;15:241–252.
14. Silva GA, Ducheyne P, Reis RL. Materials in particulate form
for tissue engineering. I. Basic concepts. J Tissue Eng Regener
Med 2007;1:4–24.
15. Terbojevich M, Cosani A, Muzzarelli RAA. Molecular param-
eters of chitosans depolymerised with the aid of papain. Carb
Polym 1996;29:63–68.
16. Calvo P, Remun˜an-Lopez C, Vila-Jato JL, Alonso MJ. Novel
hydrophilic chitosan-polyethylene oxide nanoparticles as pro-
tein carriers. J Appl Polym Sci 1997;63:125–132.
17. Sarmento B, Ribeiro A, Veiga F, Ferreira D. Development
and characterization of new insulin containing polysaccha-
ride nanoparticles. Colloid Surf B Biointerfaces 2006;53:193–
202.
18. Fernandez-Urrusuno R, Calvo P, Remun˜an-Lopez C, Vila-Jato
JL, Alonso MJ. Enhancement of nasal absorption of insu-
lin using chitosan nanoparticles. Pharm Res 1999;16:1576–
1581.
19. Grenha A, Seijo B, Remun˜an-Lopez C. Microencapsulated
chitosan nanoparticles for lung protein delivery. Eur J Pharm
Sci 2005;25:427–437.
20. Schiffman JD, Schauer CL. Cross-linking chitosan nanoﬁbers.
Biomacromolecules 2007;8:594–601.
21. Lawrie G, Keen I, Drew B, Chandler-Temple A, Rintoul L,
Fredericks P, Grøndahl L. Interactions between alginate and
chitosan biopolymers characterized using FTIR and XPS. Bio-
macromolecules 2007;8:2533–2541.
22. Volery P, Besson R, Schaffer-Lequart C. Characterization of
commercial carrageenans by Fourier transform infrared spec-
troscopy using single-reﬂection attenuated total reﬂection.
J Agricult Food Chem 2004;52:7457–7463.
23. Abad LV, Relleve LS, Aranilla CT, Rosa AMD. Properties of
radiation synthesized PVP-kappa carrageenan hydrogel
blends. Rad Phys Chem 2003;68:901–908.
1272 GRENHA ET AL.
Journal of Biomedical Materials Research Part A
